Cutacnyl

Quick links to important sections

Cutacnyl

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cutacnyl

Cutacnyl is a specialized, single-ingredient dermatological preparation intended for the topical treatment of acne.

Property Description
Active ingredient Benzoyl Peroxide (BPO)
Form Cutaneous Gel (Topical Preparation)
Pharmacological class Anti-acne agent, Antiseptic, Keratolytic
General Use Treatment of mild to moderate acne vulgaris
Origin Synthetic oxidizing agent

What Type of Medicine is Cutacnyl and What is its Composition?

Cutacnyl is fundamentally an Anti-acne agent and Antiseptic whose therapeutic function is derived entirely from the active ingredient, Benzoyl Peroxide (BPO). This composition makes Cutacnyl a monoseptic product. The active ingredient is a synthetic compound that falls into the broader pharmacological class of topical antimicrobials and keratolytic agents, clinically recognized for its efficacy against acne vulgaris. The compound's function is rooted in its nature as a potent oxidizing agent, distinguishing it from traditional topical antibiotics. The brand is generally recognized as a prescription-only medicine (POM) across several regions.

Cutacnyl's Pharmaceutical Form and General Purpose

Cutacnyl is supplied as a translucent Cutaneous Gel, formulated within an aqueous base for controlled, non-systemic application to the skin. The medication is strictly intended for topical administration, concentrating its effect at the skin’s surface.

The general purpose of Cutacnyl is to help control the processes that lead to acne. Benzoyl Peroxide functions as a Keratolytic agent, helping to shed dead skin cells and clear the pores, while simultaneously delivering an Antiseptic effect against Cutibacterium acnes, the key bacteria involved in acne development. Topical Benzoyl Peroxide may be more effective than a placebo for improving acne, indicating that the compound provides a valuable contribution to achieving clearer skin, typically in patient groups addressing facial or truncal blemishes.

What side effects are possible with Cutacnyl?

Possible Side Effects and Safety Information

Cutacnyl (benzoyl peroxide) is associated with several officially documented adverse reactions, primarily affecting the skin. The safety profile distinguishes between common, expected local reactions and rare, serious systemic events, as classified by government regulatory authorities.

Frequency-Classified Adverse Reactions

The most common adverse reactions are local skin events, classified by frequency as:

Classification Side Effect
Very Common (ge 1/10) Dry skin, Erythema (redness), Skin exfoliation (peeling), Burning sensation.
Common (ge 1/100 to <1/10) Pruritus (itching), Pain of skin (stinging), Skin irritation.
Uncommon (ge 1/1,000 to <1/100) Allergic contact dermatitis.

These reactions are often most prominent during the first weeks of treatment and are expected to improve over time.

Serious Adverse Reactions and Safety Constraints

Side effects affecting the Immune System Disorders are documented, but are rare. These include serious allergic reactions or Hypersensitivity (such as Anaphylaxis or Angioedema) and swelling of the face or blistering of the skin. Patients should be aware of these rare, clinically significant reactions.

Safety-Related Restrictions:

Official labeling includes strict limitations to reduce risk:

  • Avoid contact with the eyes, mouth, angles of the nose, and mucous membranes.
  • Do not apply on damaged skin.
  • Avoid deliberate or prolonged exposure to sunlight or UV radiation due to increased sensitivity.
  • Contact with colored materials (including hair and fabrics) may cause bleaching or discoloration.

Population-Specific Notes

Use during pregnancy is permitted only if the expected benefit justifies the potential risk. For breast-feeding, the preparation should not be applied to the chest area to prevent accidental transfer to the infant.

Overdose and Emergency Response

Overdose and When to Seek Help

Cutacnyl is a topical preparation, and the primary risk of overdose is related to excessive application on the skin, which may lead to severe local irritation. This can manifest as pronounced redness (erythema), stinging, or peeling of the skin, which are exaggerated forms of the expected local effects. If severe irritation occurs, the official advice is to reduce the frequency of application or interrupt treatment.

Immediate Medical Emergency

Two specific situations require immediate, urgent medical attention:

  1. Accidental Ingestion: If the product is accidentally swallowed, medical advice must be sought immediately.
  2. Serious Systemic Hypersensitivity Reaction: Although rare, the possibility of a serious, potentially life-threatening allergic reaction exists. Symptoms of a serious hypersensitivity reaction may include throat tightness, difficulty breathing, feeling faint, or swelling of the eyes, face, lips, or tongue. If any of these signs appear, stop use and seek emergency medical attention immediately.

Summary of Risks

Overdose Context Clinical Manifestation Required Action
Excessive Topical Use Severe local irritation, stinging Reduce frequency or stop treatment
Accidental Ingestion Undefined; assumed systemic risk Seek medical advice immediately
Hypersensitivity Reaction Difficulty breathing, facial swelling Seek emergency medical attention immediately

Therapeutic Uses of Cutacnyl

Cutacnyl is commonly used to treat mild to moderate acne. This application is generally relevant for patients experiencing a noticeable presence of blemishes on the face or body. The medication is used for managing the symptoms related to inflammatory or irritative states on the skin, and is commonly used to address both the inflamed spots—such as red bumps and pimples—and noninflammatory lesions like blackheads and whiteheads.

It is applied across therapeutic domains where additional symptomatic support is needed to address symptom clusters that may become disruptive during flare-ups. The medication provides supportive relief that helps ease the overall symptom burden and plays a role in managing the prevention of new acne spots. It is commonly integrated into maintenance regimens, and is relevant in clinical settings where it may be part of combination therapy to assist with maintaining functional stability during periods of recurrent manifestations.

“The primary goal is to help patients cope more steadily with symptom fluctuations and contribute to easing the overall symptom load.”


Quick Fact: Relief for Acne Symptoms The product is considered relevant in clinical settings that involve recurrent or episodic manifestations to support long-term skin clarity and manage active papules and comedones.

Regulatory References

  1. NIH MedlinePlus Drug Information on Benzoyl Peroxide

Eligibility and Restrictions for Use

Who Can and Cannot Use Cutacnyl?

The eligibility profile for Cutacnyl is defined by specific regulatory criteria from official governmental sources.

Absolute Contraindication

The medicine is strictly contraindicated for any individual with a known hypersensitivity or allergy to the active substance, benzoyl peroxide, or to any of the other components in the gel formulation.

Age-Group Eligibility

Cutacnyl is generally established for use in adults and adolescents 12 years of age and older. Safety and efficacy have not been established for children under 12 years of age. Regulatory documents note that there are no specific recommendations documented for use in the elderly population.

Specific Restrictions

For pregnant and breastfeeding women, use is considered conditional, permitted only when the potential benefit outweighs any potential risk. Breastfeeding women must not apply the gel to the breast area. The product must not be applied to broken, eczematous, or sunburned skin. Furthermore, use has not been studied in patients with renal (kidney) or hepatic (liver) impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory interaction profile for Cutacnyl (Benzoyl Peroxide) topical gel is strictly limited to local pharmacodynamic effects due to its minimal systemic absorption. Regulatory documents state that no formal interaction studies have been performed with systemic medicinal products, and interactions with orally administered medicines are unlikely.


Documented Interaction Patterns

The documented constraints relate exclusively to substances applied directly to the skin, which can lead to additive irritation or chemical reactions.

Interaction Entity Official Regulatory Statement
Other Topical Anti-Acne Agents Co-administration with other topical retinoids (e.g., Tretinoin, Tazarotene) or peeling, abrasive, or drying agents is restricted due to the risk of cumulative irritancy.
Topical Sulfone Products Concurrent use with topical Dapsone gel may lead to a temporary localized yellow or orange skin discoloration at the application site.
Alcohol-Containing Products Use of topical skin preparations with a high alcohol content is cautioned against, as this may result in an additive drying or irritant effect when co-administered.

Systemic Interaction Status

No clinically significant interactions are documented between Cutacnyl and oral medicinal products, food, or dietary supplements. The regulatory focus remains on preventing local adverse effects from combined topical applications.

Mechanism of Action

How Cutacnyl Works

Cutacnyl's mechanism of action relies entirely on its active ingredient, Benzoyl Peroxide (BPO), which engages three core mechanistic domains to influence the biological processes within the pilosebaceous unit.

Targeted Biological Oxidation (Bactericidal Action)

This domain covers BPO’s function as a pro-oxidant. It works by releasing free oxygen radicals within the hair follicle, leading to the rapid and irreversible oxidation and destruction of the cell components of the anaerobic bacterium, Cutibacterium acnes. This action directly reduces the microbial load, which diminishes a biological trigger for localized skin reactions.

Modulation of Follicular Cell Cohesion (Keratolytic Action)

The drug influences the biological process of cell shedding, or desquamation, by loosening the intercellular connections between follicular keratinocytes. By accelerating the turnover of epithelial cells, the mechanism discourages the accumulation of cellular debris and keratin, thereby contributing to the physiological state of an unblocked follicle.

Indirect Dampening of Innate Immune Signaling

The mechanism indirectly influences the local innate immune signaling cascade. As a physiological consequence of the reduced bacterial population and the clearance of physical pore obstructions, the triggering stimuli for immune activation are lessened. This results in the attenuation of localized innate immune activation, which is a consequence of reduced bacterial and irritant exposure.

Dosage and Administration Information

Cutacnyl is a specialized dermatological product that contains the active ingredient Benzoyl Peroxide (BPO) and is formulated as a cutaneous gel. The application protocol for the gel is defined to ensure correct administration.

Administration Guidelines

Administration Scope Description
Route of administration Topical (Cutaneous use only). The medication is not intended for internal use, including oral, ophthalmic, or intravaginal application.
Dosing schedule A thin layer of the gel, available in concentrations like 2.5%, 5%, and 10%, is applied to the affected areas. Excess application does not increase efficacy and may heighten the risk of local irritation.
Frequency pattern Treatment typically begins with an application once daily, often in the evening. The frequency may be gradually increased to twice daily if the skin tolerates the initial regimen. If drying or peeling occurs, the frequency should be temporarily reduced.
Age-group rules Adults and adolescents (12 years and older) use the standard regimen. Use in children younger than 12 years requires evaluation by a healthcare professional as standard dosing is not established for this age group.

Procedural Conditions

Prior to application, the skin should be clean and dry. The gel must avoid contact with mucous membranes, including the eyes, mouth, lips, and angles of the nose. Users are instructed to be mindful that the product is an oxidizing agent and can bleach hair or colored fabrics upon contact. The overall course of treatment should not extend beyond three continuous months without medical re-evaluation, although initial improvement is typically noted within four weeks.

These instructions collectively establish the use of Cutacnyl as a localized, titrated topical regimen under defined conditions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cutacnyl


Evidence for Use in Mild to Moderate Acne Vulgaris

Clinical evaluation of the active ingredient in Cutacnyl was studied for the context of research for mild to moderate acne, a condition characterized by fluctuating or episodic manifestations. The bulk of the research research examined comes from Randomized Controlled Trials (RCTs), which compare the product against a placebo or other acne treatments. These trials are then summarized in large-scale Systematic Reviews and Meta-Analyses to synthesize the body of available evidence.

Studies explored how the condition changed over short and intermediate time periods. The research highlights changes measured during the study period in the number of acne lesions—specifically, both non-inflamed spots (like blackheads and whiteheads) and inflamed spots (like red bumps). Research highlights changes measured in the observed populations, specifically related to changes in lesion counts.


Study Endpoints and Trial Comparisons

This part describes the outcomes related to physical discomfort that research examined to evaluate the outcomes of the research. One primary way results were observed in studies was by counting the number of acne lesions present on a participant’s skin at different stages of the trial. Studies monitored these outcomes describing episodic or acute changes in both inflammatory and non-inflammatory spots.

In addition to counting lesions, another common outcome that research examined is the Investigator’s Global Assessment (IGA). This is a rating scale used in research exploring how symptoms change over time. When evaluated in comparisons against a placebo gel, some trials data show patterns related to changes in lesion counts over defined time intervals. For comparisons with other topical treatments, the evidence is limited and findings were mixed across different studies.


Quality of Evidence and Remaining Uncertainties

Scientific assessments from groups like the Cochrane Collaboration have noted that the evidence quality varies across studies. Findings indicate that the certainty remains low or very low across meta-analyses when data from different trials are combined. Follow-up durations were limited in many primary trials, and long-term effects are not fully established by extensive controlled trial data extending past six months.

Data for certain groups remain insufficient, particularly for older adults, or individuals with certain underlying health conditions, as they were often excluded from the core clinical research. Research provides context but not individual predictions.

Key Studies & References Benzoyl Peroxide Topical Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Cutacnyl (FAQ)

Q: Is Cutacnyl the same as other benzoyl peroxide products?

Cutacnyl's active ingredient is Benzoyl Peroxide (BPO), which is found in many other anti-acne products. The primary differences between products often lie in the concentration (such as 2.5%, 5%, or 10%) and the formulation base (like a gel or a cream). These variations can influence how well the skin tolerates the product and how it is applied.

Q: What is the difference between Cutacnyl 2.5% and 5%?

Higher concentrations of the active ingredient, such as 5% compared to 2.5%, are generally associated with higher efficacy. However, the official product information indicates that they also carry a higher risk of causing local skin side effects, like excessive dryness, redness, and peeling. Treatment regimens often begin with a lower strength to allow the skin to adjust and build tolerance.

Q: Can I use other topical acne treatments at the same time as Cutacnyl?

Regulatory information advises caution regarding other topical treatments. Co-administration with other topical retinoids or products that are peeling, abrasive, or drying is generally restricted because of the risk of cumulative skin irritation. Concurrent use with topical Dapsone gel may also lead to a temporary localized yellow or orange skin discoloration at the application site.

Q: What do official documents say about avoiding waxing or hair removal while using this product?

Official safety restrictions caution that the product is an oxidizing agent that can bleach hair or colored fabrics. While official documents do not explicitly mention hair removal methods like waxing or shaving, it is generally recognized that practices that increase skin irritation should be considered carefully, given Cutacnyl’s tendency to cause local side effects.

Q: Can I use Cutacnyl if I have eczema or psoriasis?

The medicine is strictly cautioned against use on broken, eczematous, or sunburned skin. If an individual has a condition like eczema or psoriasis, they should be aware of the increased risk of irritation and hypersensitivity, and the application of the product is restricted to clear skin areas.

Q: Is there a link between the concentration of Cutacnyl and the likelihood of side effects?

Yes, official administration guidelines indicate that using a higher concentration or applying an excess amount of the gel may heighten the risk of local irritation. Common side effects like dryness, redness, and peeling are generally managed by temporarily reducing the frequency or using a lower concentration.

Q: What does official guidance say about using other skin products simultaneously?

Regulatory guidance specifically cautions against using topical skin preparations with a high alcohol content because they may cause an additive drying or irritant effect. General non-medicated products like gentle cleansers and oil-free moisturizers are often used to help manage the expected dryness caused by the treatment.

Q: Does Cutacnyl lighten my skin or cause bleaching?

Regulatory documents explicitly warn that the product can cause bleaching of hair and colored fabrics. Official product information does not describe it as an agent for skin lightening. However, the irritation it causes may be more noticeable or visible on darker skin tones.

Q: How quickly can I expect to see changes after starting Cutacnyl?

Initial improvement in the skin condition is typically noted within four weeks of starting treatment. The full extent of the treatment's effect may take a longer duration, with initial improvement noted within four weeks.

Q: What should I do if my skin gets very red or peels a lot when using Cutacnyl?

Redness (erythema), dryness, and peeling (exfoliation) are listed as very common and expected side effects. Official guidance states that if bothersome drying or peeling occurs, the application frequency should be temporarily reduced. If irritation becomes severe or is not manageable, the instructions recommend temporarily stopping the use of the product and consulting a healthcare professional.

Q: Can Cutacnyl be used on parts of the body other than the face?

The drug is intended for topical use on affected areas of the skin. While clinical research and guidance often focus on facial blemishes, the product has been studied for use on truncal blemishes, which refers to acne on the chest and back. It can be used on acne-affected skin beyond the face.

Q: Is it normal to feel a stinging sensation right after applying Cutacnyl?

Yes, feeling a stinging sensation and a burning sensation are listed in official documents as common and very common adverse reactions, respectively. This is an expected local effect, particularly during the initial phase of treatment, and often subsides over time as the skin adjusts.

Q: Can Cutacnyl interact with my birth control pills?

Formal interaction studies with systemic medicinal products, including oral contraceptives, have not been conducted due to the medication’s route of administration. Interactions with orally administered medicines are considered unlikely because the active ingredient, Benzoyl Peroxide, has minimal systemic absorption into the body.

Q: Are there any specific skincare ingredients I must avoid while using this medicine?

You should avoid certain categories of topical products due to the risk of cumulative skin irritation. These include other topical retinoids, products designed to cause peeling or abrasion, and preparations with a high alcohol content.

Q: Is it possible to be allergic to an ingredient in Cutacnyl?

Yes. The medicine is strictly contraindicated for anyone with a known hypersensitivity or allergy to the active substance, Benzoyl Peroxide, or to any of the other components. Allergic contact dermatitis is also listed as an uncommon, though possible, adverse reaction.

Q: How does the medicine know where to work on the skin?

The active ingredient, Benzoyl Peroxide, works by targeting the specific biological processes that occur within the pilosebaceous unit—the hair follicle and oil gland complex—where acne begins. It releases oxygen radicals inside the follicle and influences cell shedding, concentrating its effect at the site of acne development.

Q: Does Cutacnyl make acne worse before it gets better?

While not described as 'worsening acne,' the most common side effects like redness, peeling, and dryness are often most prominent during the first weeks of treatment. This initial irritation is expected to improve over time as the skin adjusts to the medication.

Q: Can I use Cutacnyl if I have sensitive skin?

Official warnings from regulatory sources caution against using products containing Benzoyl Peroxide on very sensitive skin. Irritation and dryness are more likely to occur, and measures such as using a lower concentration or reducing the frequency of application are described as methods to minimize effects.

Q: What should I look out for if I think a side effect is getting serious?

Serious adverse reactions are rare, but patients should be aware of signs of immediate hypersensitivity (allergic reaction). These signs include swelling of the face, blistering of the skin, or difficulties with breathing or swallowing. Immediate medical attention is required if these rare, severe reactions occur, according to official guidance.

Q: Does Cutacnyl help with the redness associated with acne?

Official documents describe that the mechanism of action leads to the attenuation (reduction) of localized innate immune signaling. Since this signaling is linked to the development of inflammation, this effect contributes to the calming of the skin reactions associated with acne, including redness and swelling.

Q: Is the medication absorbed into the body, or does it just work on the surface?

The product is formulated for topical use, and its interaction profile is strictly limited due to its minimal systemic absorption. The active ingredient, Benzoyl Peroxide, is primarily absorbed by the skin where it is metabolized into a different substance, benzoic acid.

Q: Are there different storage conditions required for Cutacnyl?

Official storage instructions specify temperature ranges (typically not above 25 C or 30 C) and state that the product must not be frozen. It must also be kept in its original container, protected from direct sunlight, and stored out of the reach of children.

Q: Do studies cover how long the effects of Cutacnyl last after stopping treatment?

Scientific assessments have noted that the follow-up durations in many clinical trials were limited. Consequently, long-term effects are not fully established by extensive controlled trial data that extends beyond six months. Data on post-treatment duration of effects is insufficient in core regulatory research.

Q: Can Cutacnyl be used with common sunscreen products?

Yes. Official labeling advises patients to avoid deliberate or prolonged exposure to sunlight or UV radiation due to increased skin sensitivity. When sun exposure cannot be completely avoided, patients are advised to wear broad-spectrum sunscreen and protective clothing.

Q: Are there specific parts of the body that should not be treated with Cutacnyl?

The gel must avoid contact with all mucous membranes, including the eyes, mouth, lips, and angles of the nose. It should also not be applied to the breast area during breastfeeding, or to any areas of damaged, eczematous, or sunburned skin.

How should Cutacnyl be stored and disposed of?

Official Storage and Disposal Guidelines

Storage and disposal requirements for Cutacnyl (Benzoyl Peroxide gel) are mandated by regulatory agencies to ensure product stability and patient safety.

Storage Conditions

Requirement Official Instruction
Temperature Do not store above 25 C or 30 C (varies by specific product) and do not freeze.
Protection Keep in the original, tightly closed container, protected from direct sunlight.
Child Safety Must be stored out of the reach and sight of children.

Stability and Handling

The gel may cause bleaching; therefore, contact with hair, clothing, and colored fabrics must be avoided. After the first opening, the in-use shelf life is typically limited (e.g., 3 to 6 months), after which the product must be discarded. Users should wash their hands after application.

Disposal

Unused or expired medicinal product and related waste material must be disposed of in accordance with local regulatory requirements. Disposal must avoid environmental contamination, particularly concerning the aquatic environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cutacnyl found in:

A-Z Index: